Bristol-Myers cholestyramine
Executive Summary
FDA has approved ANDA suitability petitions for cholestyramine tablets equivalent to 800 mg resin/tablet and cholestyramine capsules equivalent to 500 mg resin/capsule. The listed drug is Mead Johnson's Questran powder, 4 gm resin/pack.